Hilgenfeldt U, Linke R, König W
Department of Pharmacology, University of Heidelberg, F.R.G.
J Cardiovasc Pharmacol. 1990;15 Suppl 6:S17-9.
Because all antibodies to bradykinin described to date more or less cross-react with larger and smaller bradykinin derivatives, the aim of the present study was the induction of a specific antibody against bradykinin. A bradykinin derivative, containing a Cys residue at position 6 instead of Ser, was linked to BSA by using a new heterobifunctional cross-linking reagent, the N-maleimido-6-aminocaproyl ester of 1-hydroxy-2-nitro-4-benzenesulfonic acid (mal-sac-HNSA). The Cys6-bradykinin derivative conjugated via the SH group to BSA was used to elicit bradykinin-specific antibodies in rabbits. After the fifth booster injection, the cross-reactivity of this antiserum with kallidin is 4 X 10(-3) when compared with bradykinin. The cross-reactivity of the de-Arg1-bradykinin derivative was 2 X 10(-4), indicating that the antibody requires the free N-terminus. The cross-reactivity of bradykinin and de-Arg9-bradykinin was nearly identical. However, de-Arg9-de-Phe8-bradykinin has a binding of 6 X 10(-3). From these data, it can be concluded that due to the ring-like structure of bradykinin, the coupling of bradykinin in the center of the molecule will elicit an antiserum that needs both the free N-terminal as well as the C-terminal phenylalanine and arginine residues for antibody recognition.
由于迄今为止所描述的所有抗缓激肽抗体或多或少都与大小不同的缓激肽衍生物发生交叉反应,因此本研究的目的是诱导产生一种针对缓激肽的特异性抗体。一种在第6位含有半胱氨酸残基而非丝氨酸的缓激肽衍生物,通过使用一种新的异双功能交联剂1-羟基-2-硝基-4-苯磺酸的N-马来酰亚胺-6-氨基己酯(mal-sac-HNSA)与牛血清白蛋白(BSA)相连。通过SH基团与BSA偶联的Cys6-缓激肽衍生物用于在兔体内引发缓激肽特异性抗体。在第五次加强注射后,与缓激肽相比,这种抗血清与赖氨酰缓激肽的交叉反应性为4×10⁻³。去-Arg1-缓激肽衍生物的交叉反应性为2×10⁻⁴,表明该抗体需要游离的N末端。缓激肽和去-Arg9-缓激肽的交叉反应性几乎相同。然而,去-Arg9-去-Phe8-缓激肽的结合率为6×10⁻³。从这些数据可以得出结论,由于缓激肽的环状结构,将缓激肽偶联在分子中心会引发一种抗血清,该抗血清需要游离的N末端以及C末端的苯丙氨酸和精氨酸残基才能识别抗体。